Skip to main content
Passa alla visualizzazione normale.

ANTONIO LO CASTO

Italian position paper (SIPMO‐SICMF) on medication‐related osteonecrosis of the jaw (MRONJ)

  • Authors: Bedogni Alberto, Mauceri Rodolfo, Fusco Vittorio, Bertoldo Francesco, Bettini Giordana, Di Fede Olga, Lo Casto Antonio, Marchetti Claudio, Panzarella Vera, Saia Giorgia, Vescovi Paolo, Campisi Giuseppina
  • Publication year: 2024
  • Type: Review essay (rassegna critica)
  • OA Link: http://hdl.handle.net/10447/639757

Abstract

Objective: This paper aims to describe the 2023 update position paper on MRONJ developed by the Italian Societies of Oral Pathology and Medicine (SIPMO) and of Maxillofacial Surgery (SICMF). Methods: This is the second update following the 2013 and 2020 Italian position papers by the Expert panel, which is a representation of the two scientific societies (SIPMO and SICMF). The paper is based on an extensive analysis of the available literature from January 2003 to February 2020, and the subsequent review of literature conducted between March 2020 and December 2022 to include all new relevant published papers to confirm or modify the previous set of recommendations. Methods: This is the second update following the 2013 and 2020 Italian position papers by the Expert panel, which is a representation of the two scientific societies (SIPMO and SICMF). The paper is based on an extensive analysis of the available literature from January 2003 to February 2020, and the subsequent review of literature conducted between March 2020 and December 2022 to include all new relevant published papers to confirm or modify the previous set of recommendations. Results: This position paper highlights the main issues of MRONJ on risk estimates, disease definition, diagnostic pathway, individual risk assessment, and the fundamental role of imaging in the diagnosis, classification, and management of MRONJ. Conclusion: The Expert Panel confirmed the MRONJ definition, the diagnostic work-up, the clinical-radiological staging system and the prophylactic drug holiday, as recognized by SIPMO-SICMF; while, it presented novel indications regarding the categories at risk of MRONJ, the prevention strategies, and the treatment strategies associated with the therapeutic drug holiday.